|
7/9/98
HALLUCINOGENS Epidemiology
1997 Monitoring the Future conducted by the University of Michigan's Survey Research Center at the Institute for Social Research 1355 Institute for Social Research P.O. Box 1248 Ann Arbor, MI 48106 [www.isr.umich.edu/src/mtf] 1996 Preliminary Estimates From the Drug Abuse Warning Network (DAWN): Preliminary Estimates of Drug-Related Emergency Department Episodes Substance Abuse and Mental Health Services Administration Office of Applied Studies, Advance Report Number 17, August 1996 [www.health.org/pubs/96dawn/ar17.htm] Chilcoat HD. Schutz CG. Age-specific patterns of hallucinogen use in the US population: an analysis using generalized additive models. Drug & Alcohol Dependence. 43(3):143-53, 1996 Dec 11 Assessment & Screening
Moeller MR. Hartung M. Ecstasy and related substances--serum levels in impaired drivers Journal of Analytical Toxicology. 21(7):591, 1997 Nov-Dec Li Z. Goc-Szkutnicka K. McNally AJ. Pilcher I. Polakowski S. Vitone S. Wu RS. Salamone SJ. New synthesis and characterization of (+)-lysergic acid diethylamide (LSD) derivatives and the development of a microparticle-based immunoassay for the detection of LSD and its metabolites. Bioconjugate Chemistry. 8(6):896-905, 1997 Nov-Dec Helmlin HJ. Bracher K. Bourquin D. Vonlanthen D. Brenneisen R. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS Journal of Analytical Toxicology. 20(6):432-40, 1996 Oct Rothe M. Pragst F. Spiegel K. Harrach T. Fischer K. Kunkel J. Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Science International. 89(1-2):111-28, 1997 Sep 19 Treatment
Schuckit MA: Hallucinogens and Related Drugs, In Drug and Alcohol Abuse: A clinical guide to diagnosis and treatment, Plenum Press, 1995:188-205 Bonson KR. Buckholtz JW. Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 14(6):425-36, 1996 Jun Neurobiology
Vollenweider FX. Leenders KL. Scharfetter C. Maguire P. Stadelmann O. Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16(5):357-72, 1997 May Abraham HD. Duffy FH. Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition. Psychiatry Research. 67(3):173-87, 1996 Oct 7 Seiden LS. Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Research Monograph. 163:251-76, 1996 Strassman RJ. Qualls CR. Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological Psychiatry. 39(9):784-95, 1996 May 1 Almaula N. Ebersole BJ. Ballesteros JA. Weinstein H. Sealfon SC. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Molecular Pharmacology. 50(1):34-42, 1996 Jul Overview
Morgan JP: Designer Drugs. In Substance Abuse: A Comprehensive Textbook, Third Edition, Eds. Lowinson JH, Ruiz P, Millman RB, Langrod JG. Williams & Wilkins, 1997:264-268 Grob CS, Poland RE: MDMA. In Substance Abuse: A Comprehensive Textbook, Third Edition, Eds. Lowinson JH, Ruiz P, Millman RB, Langrod JG. Williams & Wilkins, 1997:269-275 Abraham HD. Aldridge AM. Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 14(4):285-98, 1996 Apr NIDA Capsule - LSD [http://www.nida.nih.gov/NIDACapsules/NCLSD.html] NIDA Infofax - LSD [http://www.nida.nih.gov/Infofax/lsd.html] NIDA Capsule - Designer Drugs [http://www.nida.nih.gov/NIDACapsules/NCDesigner.html] NIDA Capsule - Ecstasy [http://www.nida.nih.gov/NIDACapsules/NCMDMA.html] NIDA Notes, April 1997 - Study Takes a Closer Look at "Ecstasy" Use
Co-morbid Issues Specific
Spatt J. Glawar B. Mamoli B. A pure amnestic syndrome after MDMA ("ecstasy") ingestion. Journal of Neurology, Neurosurgery & Psychiatry. 62(4):418-9, 1997 Apr Morehead DB. Exacerbation of hallucinogen-persisting perception disorder with risperidone Journal of Clinical Psychopharmacology. 17(4):327-8, 1997 Aug Public Social Policy Issues
Micke MM. The case of hallucinogenic plants and the Internet. Journal of School Health. 66(8):277-80, 1996 Oct Lyttle T. Goldstein D. Gartz J. Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. Journal of Psychoactive Drugs. 28(3):267-90, 1996 Jul-Sep Strassman RJ. Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. Journal of Nervous & Mental Disease. 183(3):127-38, 1995 Mar Rudgley R. The archaic use of hallucinogens in Europe: an archaeology of altered states [editorial]. Addiction. 90(2):163-4, 1995 Feb Medical Complications
Borowiak KS. Ciechanowski K. Waloszczyk P. Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. Journal of Toxicology - Clinical Toxicology. 36(1-2):47-9, 1998 Cunningham M. Ecstasy-induced rhabdomyolysis and its role in the development of acute renal failure. Intensive & Critical Care Nursing. 13(4):216-23, 1997 Aug Box SA. Prescott LF. Freestone S. Hyponatraemia at a rave. Postgraduate Medical Journal. 73(855):53-4, 1997 Jan Parr MJ. Low HM. Botterill P. Hyponatraemia and death after "ecstasy" ingestion. Medical Journal of Australia. 166(3):136-7, 1997 Feb 3. Demirkiran M. Jankovic J. Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clinical Neuropharmacology. 19(2):157-64, 1996 Apr Greene GS. Patterson SG. Warner E. Ingestion of angel's trumpet: an increasingly common source of toxicity. Southern Medical Journal. 89(4):365-9, 1996 Apr. Franz M. Regele H. Kirchmair M. Kletzmayr J. Sunder-Plassmann G. Horl WH. Pohanka E. Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. Nephrology, Dialysis, Transplantation. 11(11):2324-27, 1996 Nov Kawasaki A. Purvin V. Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD). Archives of Ophthalmology. 114(1):47-50, 1996 Jan. Special Populations
Grob CS. McKenna DJ. Callaway JC. Brito GS. Neves ES. Oberlaender G. Saide OL. Labigalini E. Tacla C. Miranda CT. Strassman RJ. Boone KB. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of Nervous & Mental Disease. 184(2):86-94, 1996 Feb Adolescents - NIDA Mind of Matter -The Brains Response to Hallucinogens http://www.nida.nih.gov/MOM/HALL/MOMHALL1.html
|